Product Image

Contributor Information

  • Name Ayham Alnabulsi
  • Institute Vertebrate Antibodies Limited

Tool Details

  • Tool name: Anti-Cytochrome P450 3A7 [F19P2H2]
  • Clone: F19 P2 H2
  • Tool type: Antibodies
  • Tool sub-type: Primary antibody
  • Class: Monoclonal
  • Conjugate: Unconjugated
  • Reactivity: Human
  • Host: Mouse
  • Application: ELISA ; IHC ; WB
  • Strain: Balb/c
  • Description: This monoclonal antibody (MAb), when used in conjunction with the Mab specific to CYP3A5 clone F18 P3 B6, is able to differentiate between the CYP450 family 3 members: CYP3A5 and CYP3A7
  • Immunogen: Ovalbumin-conjugated synthetic peptide ESRDETVSGA (C-terminal sequence)
  • Isotype: IgG1 kappa
  • Research area: Cancer; Tissue-specific biology; Cell signaling and signal transduction; Metabolism

  • For Research Use Only

Target Details

  • Target: CYP3A7- Cytochrome P450 3A7 (EC 1.14.14.1) (CYPIIIA7) (P450-HFLA)
  • Target background: This monoclonal antibody (MAb), when used in conjunction with the Mab specific to CYP3A5 clone F18 P3 B6, is able to differentiate between the CYP450 family 3 members: CYP3A5 and CYP3A7

Application Details

  • Application: ELISA ; IHC ; WB

Handling

  • Format: Liquid
  • Concentration: 0.9-1.1 mg/ml
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15°C to -25°C
  • Shipping conditions: Shipping at 4°C

Documentation

Related Tools

Product Image

Anti-CD45RA [4KB5]

#151362
Product Image

Anti-PDECGF [PGF 44C]

#151220
Product Image

Anti-Thyroglobulin [2H11]

#154801

References

  • •  Zia et al. 2015. Int J Exp Pathol. 96(2):81-6. PMID: 25670065.
  • •  CYP3A isoforms in Ewing's sarcoma tumours: an immunohistochemical study with clinical correlation.
  • •  Downie et al. 2005. Clin Cancer Res. 11(20):7369-75. PMID: 16243809.
  • •  Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers.
  • •  Kumarakulasingham et al. 2005. Clin Cancer Res. 11(10):3758-65. PMID: 15897573.
  • •  Cytochrome p450 profile of colorectal cancer: identification of markers of prognosis.